Mizuho lowered the firm’s price target on Kura Oncology (KURA) to $30 from $32 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology: Promising Clinical Trials and Stable Financials Justify Buy Rating
- Kura, Kyowa say ziftomenib abstract accepted for EHA Congress
- Kura Oncology’s Promising Market Position and Growth Prospects Justify Buy Rating
- Syndax price target raised to $17 from $16 at Scotiabank
- Kura Oncology’s Strategic Advancements and Promising Pipeline Drive Buy Rating